Skip to main content

Table 4 Factors associated with receiving a relative dose-intensity lower than 85% - results of a multivariate logistic regression model (n = 380)

From: A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival

  

Odds ratios

p-value

[95% Confidence Interval]

Gender

Male

1

  

Female

1.32

0.361

[0.73; 2.37]

Age a

<59 y

1

  

59 - 73 y

1.06

0.902

[0.41; 2.77]

>73 y

4.42

0.019

[1.27; 15.35]

Socioeconomic status b (quintile of EDI national scores)

1: highly favoured

1

  

2: favoured

1.49

0.387

[0.60; 3.67]

3: intermediate level

0.32

0.025

[0.12; 0.86]

4: deprived

0.79

0.625

[0.31; 2.01]

5: highly deprived

0.72

0.526

[0.26; 1.98]

Comorbidity

none

1

  

at least 1

1.13

0.704

[0.59; 2.18]

Standard International prognostic index c (sIPI)

very good

1

  

good

1.32

0.612

[0.45; 3.86]

poor

4.60

0.008

[1.48; 14.30]

Chemotherapy regimens d

R- CHOP 21 or R-CHVP

1

  

R- CHOP 14

7.65

0.001

[2.35; 24.92]

R- ACVBP

1.30

0.737

[0.15; 6.06]

R-miniCHOP or R-mini CHVP

0.66

0.429

[0.24; 1.87]

other

0.09

0.046

[0.01; 0.96]

Place of treatment e

Private centres

1

  

TUMC

0.23

0.003

[0.09; 0.60]

Community hospitals

1.11

0.780

[0.55; 2.23]

  1. Notes a, b, c, d, and e indicate the global p-value; a: p = 0.027; b: p = 0.025; c: p < 0.001; d: p = 0.002; e: p = 0.002.
  2. DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; EDI: European deprivation index; TUMC: Toulouse university medical centre.